169 related articles for article (PubMed ID: 31628530)
1. [Salivary gland malignancies-highlights of the 2019 ASCO Annual Meeting].
Doescher J; Schuler PJ; Greve J; Meyer MF; Weissinger S; Hoffmann TK; Laban S
HNO; 2019 Dec; 67(12):931-934. PubMed ID: 31628530
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for salivary gland malignancy: current status and future perspectives.
Imamura Y; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ota I; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Yokota T; Okano S; Tanaka K; Onoe T; Ariizumi Y; Homma A
Jpn J Clin Oncol; 2022 Apr; 52(4):293-302. PubMed ID: 35134985
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler P; Hoffmann TK; Laban S
HNO; 2019 Dec; 67(12):905-911. PubMed ID: 31612261
[TBL] [Abstract][Full Text] [Related]
4. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
7. [Studies on radiotherapy of head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Ott S; Wiegel T; Hoffmann TK; Petersen C; Tribius S; Laban S
HNO; 2019 Dec; 67(12):918-924. PubMed ID: 31659379
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
10. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
11. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.
Schneider T; Strehl A; Linz C; Brands R; Hartmann S; Beckford F; Rosenwald A; Kübler AC; Müller-Richter UD
Clin Oral Investig; 2016 Apr; 20(3):541-51. PubMed ID: 26245271
[TBL] [Abstract][Full Text] [Related]
13. Management of salivary gland carcinomas - a review.
Wang X; Luo Y; Li M; Yan H; Sun M; Fan T
Oncotarget; 2017 Jan; 8(3):3946-3956. PubMed ID: 27992367
[TBL] [Abstract][Full Text] [Related]
14. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
15. [Malignant epithelial salivary gland tumors. Clinical review of 2 decades].
Kokemüller H; Brüggemann N; Brachvogel P; Eckardt A
Mund Kiefer Gesichtschir; 2004 May; 8(3):191-201. PubMed ID: 15138857
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronan and CD44 expression in minor salivary gland tumors.
Xing R; Regezi JA; Stern M; Shuster S; Stern R
Oral Dis; 1998 Dec; 4(4):241-7. PubMed ID: 10200702
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
Dori S; Vered M; David R; Buchner A
J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
[TBL] [Abstract][Full Text] [Related]
18. Cancers of the Major Salivary Gland.
Son E; Panwar A; Mosher CH; Lydiatt D
J Oncol Pract; 2018 Feb; 14(2):99-108. PubMed ID: 29436307
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma.
Beppu S; Ito Y; Fujii K; Saida K; Takino H; Masaki A; Murase T; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Ijichi K; Murakami S; Inagaki H
Histopathology; 2017 Aug; 71(2):305-315. PubMed ID: 28370175
[TBL] [Abstract][Full Text] [Related]
20. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Skálová A; Stenman G; Simpson RHW; Hellquist H; Slouka D; Svoboda T; Bishop JA; Hunt JL; Nibu KI; Rinaldo A; Vander Poorten V; Devaney KO; Steiner P; Ferlito A
Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
